Chengdu Bright Eye Hospital Group Co., Ltd. (SZSE:301239) Insiders, Who Hold 44% of the Firm Would Be Disappointed by the Recent Pullback
Chengdu Bright Eye Hospital Group Co., Ltd. (SZSE:301239) Insiders, Who Hold 44% of the Firm Would Be Disappointed by the Recent Pullback
Key Insights
關鍵洞察
- Chengdu Bright Eye Hospital Group's significant insider ownership suggests inherent interests in company's expansion
- The top 3 shareholders own 50% of the company
- Institutions own 28% of Chengdu Bright Eye Hospital Group
- 成都明亮眼科醫院集團顯著的內部股權表明該公司在擴張方面的固有利益
- 前三大股東擁有公司50%的股份
- 機構持有成都明亮眼科醫院集團28%的股份
A look at the shareholders of Chengdu Bright Eye Hospital Group Co., Ltd. (SZSE:301239) can tell us which group is most powerful. The group holding the most number of shares in the company, around 44% to be precise, is individual insiders. In other words, the group stands to gain the most (or lose the most) from their investment into the company.
查看成都明亮眼科醫院集團有限公司(深交所代碼:301239)的股東可以告訴我們哪個集團最強大。 持有公司最多股份的集團,大約佔44%的股份,主要是個人內部人士。 換句話說,這個集團從投資公司中得到的收益最多(或損失最多)。
As market cap fell to CN¥8.3b last week, insiders would have faced the highest losses than any other shareholder groups of the company.
上週市值降至83億人民幣,內部人士的損失將比公司的其他股東群體更高。
Let's take a closer look to see what the different types of shareholders can tell us about Chengdu Bright Eye Hospital Group.
讓我們更仔細地看看不同類型的股東能告訴我們關於成都明眸醫院集團的信息。
What Does The Institutional Ownership Tell Us About Chengdu Bright Eye Hospital Group?
機構持股對成都明眸醫院集團意味着什麼?
Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.
機構通常在向自己的投資者報告時,會與基準進行比較,因此一旦股票被納入主要指數,他們通常對該股票會更加熱情。我們預期大多數公司在登記時都會有一些機構,尤其是當它們正在增長時。
We can see that Chengdu Bright Eye Hospital Group does have institutional investors; and they hold a good portion of the company's stock. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Chengdu Bright Eye Hospital Group, (below). Of course, keep in mind that there are other factors to consider, too.
我們可以看到成都明眸醫院集團確實有機構投資者,他們持有公司股票的較大部分。這意味着爲這些機構工作的分析師已經查看了這隻股票並且喜歡它。但和其他任何人一樣,他們也可能是錯的。如果兩個大型機構投資者試圖同時賣出某隻股票,股票價格大幅下跌並不少見。因此,查看成都明眸醫院集團過去的盈利軌跡是值得的(見下文)。當然,還要記住,還有其他因素需要考慮。
Chengdu Bright Eye Hospital Group is not owned by hedge funds. Looking at our data, we can see that the largest shareholder is Xuyang Xu with 43% of shares outstanding. Meanwhile, the second and third largest shareholders, hold 4.0% and 3.1%, of the shares outstanding, respectively.
成都明亮眼科醫院集團並不被對沖基金擁有。根據我們的數據,我們可以看到最大的股東是徐陽,持有43%的流通股。與此同時,第二和第三大股東,分別持有4.0%和3.1%的流通股。
A more detailed study of the shareholder registry showed us that 3 of the top shareholders have a considerable amount of ownership in the company, via their 50% stake.
對股東登記冊的更詳細研究顯示,排名前幾的大股東中有3個持有公司相當數量的股份,擁有50%的股份。
While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. While there is some analyst coverage, the company is probably not widely covered. So it could gain more attention, down the track.
雖然研究公司機構持股數據是有意義的,但研究分析師情緒也同樣重要,以了解風向如何。儘管有一定的分析師覆蓋,但這家公司可能並沒有被廣泛報道。因此它在未來可能會獲得更多關注。
Insider Ownership Of Chengdu Bright Eye Hospital Group
成都明亮眼科醫院集團的內部持股
The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
內幕交易者的定義在不同國家之間可能會略有不同,但董事會成員始終被計算在內。公司管理層運行業務,但首席執行官將向董事會負責,即使他或她是董事會的成員。
Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.
當內幕所有權表明領導者像真正的公司所有者那樣思考時,這是積極的。然而,高內幕所有權也可能賦予公司內部小集團巨大的權力。在某些情況下,這可能是負面的。
Our most recent data indicates that insiders own a reasonable proportion of Chengdu Bright Eye Hospital Group Co., Ltd.. It has a market capitalization of just CN¥8.3b, and insiders have CN¥3.7b worth of shares in their own names. That's quite significant. Most would be pleased to see the board is investing alongside them. You may wish to access this free chart showing recent trading by insiders.
我們最新的數據表明,內部人士擁有成都明亮眼醫院集團有限公司相當比例的股份。它的市值僅爲83億人民幣,內部人士名下持有37億人民幣的股份。這是相當顯著的。大多數人看到董事會與他們共同投資會感到高興。您可能希望查看這張免費的圖表,展示了內部人士最近的交易情況。
General Public Ownership
公衆持股
The general public-- including retail investors -- own 19% stake in the company, and hence can't easily be ignored. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.
公衆,包括散戶投資者,擁有該公司的19%股份,因此不能被輕易忽視。這種所有權規模雖然相當可觀,但如果決策與其他大股東不同,可能不足以改變公司政策。
Private Company Ownership
私有公司所有權
It seems that Private Companies own 8.9%, of the Chengdu Bright Eye Hospital Group stock. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.
似乎私營公司持有成都明眸醫院集團8.9%的股票。單憑這一事實很難得出任何結論,因此值得研究一下這些私營公司的所有者。有時,內部人或其他相關方可能通過一家獨立的私營公司對一家上市公司的股票有利益。
Next Steps:
下一步:
I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Consider for instance, the ever-present spectre of investment risk. We've identified 2 warning signs with Chengdu Bright Eye Hospital Group , and understanding them should be part of your investment process.
我發現了解一家公司究竟由誰擁有非常有趣。但要真正獲得洞察,我們還需要考慮其他信息。例如,要考慮投資風險這個始終存在的幽靈。我們已識別出成都明眸醫院集團的2個警示信號,理解它們應該成爲你的投資過程的一部分。
If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.
如果你和我一樣,可能想考慮這家公司是會增長還是會縮減。幸運的是,你可以查看這份免費報告,其中顯示了分析師對其未來的預測。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注意:本文中的數字是根據過去十二個月的數據計算得出的,指的是截至財務報表日期的月份最後一天的12個月期間。這可能與完整年度的年報數字不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有反饋?對內容有疑慮?請直接與我們聯繫。或者,發送電子郵件至 editorial-team (at) simplywallst.com。
這篇來自Simply Wall St的文章是一般性的。我們根據歷史數據和分析師預測提供評論,採用無偏見的方法,我們的文章並不旨在提供財務建議。它不構成對任何股票的買入或賣出建議,也未考慮到您的目標或財務狀況。我們旨在爲您提供以基本數據驅動的長期分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St在提到的任何股票中均沒有持倉。